FibroGen
Zhao Hongda is a scientist at FibroGen since August 2008, focusing on the discovery of small molecule Prolyl-hydroxylase Inhibitors (PHIs) aimed at treating anemia, providing cardioprotection, and developing cancer therapies, along with process development for intermediate-size scale-up to support preclinical development. Prior experience includes a role as a Postdoctoral Research Fellow at the University of Texas Southwestern Medical Center from May 2006 to May 2008, where Zhao synthesized and derivatized cyclic peptides to create a series of structurally diverse compounds and utilized reverse-phase HPLC for product separation. Additionally, Zhao held the position of Group Leader at Chempacific Corp in 2008, supervising and conducting API synthesis under cGMP conditions. Zhao earned a Ph.D. in Synthetic Organic Chemistry from The University of Texas at Austin between 2001 and 2006, following a Master of Science in the same field from Tulane University from 1999 to 2001.
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.